Highlight
– Dapagliflozin significantly improved the slope of estimated glomerular filtration rate (eGFR) over 12 months in heart transplant recipients. – The DAPARHT trial was a rigorous, multicenter, double-blind, placebo-controlled randomized study conducted in six Northern European heart transplant centers. – Treatment with dapagliflozin showed no unexpected safety concerns or increased adverse events, including infections. – This represents the first large-scale evidence supporting SGLT2 inhibitors as a renal protective approach in the heart transplant population.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
